Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Final Thoughts on the Treatment of Breast Cancer

July 16th 2019

Genomic/Somatic Molecular Alteration Evaluation

July 16th 2019

Treatment of Germline BRCA with PARP and Checkpoint

July 16th 2019

The Use of Chemotherapy and Checkpoint Inhibitors for TNBC

July 16th 2019

Immunotherapy for Triple-Negative Breast Cancer

July 16th 2019

Approach to Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 16th 2019

Emerging Agents for Relapsed-Refractory HER2+ MBC

July 16th 2019

Treatment Options for Metastatic HER2+ Breast Cancer

July 16th 2019

Treatment of Homogeneous Tumors vs Heterogenetic Tumors

July 16th 2019

Trials That Shaped HER2-Positive Therapy for BC

July 16th 2019

TAILORx Trial for ER-Positive Patients

July 16th 2019

Implications of Finding Patients With PIK3CA Mutations

July 16th 2019

Treatment After Progression on CDK4/6

July 16th 2019

Predictive and Prognostic Biomarkers and Resistance Mutations

July 16th 2019

MONALEESA-2 and Choosing Among the CDK4/6

July 16th 2019

Introduction and Overview of the MONALEESA-7 Trial

July 16th 2019

Dr. Velez on Managing Neratinib-Associated Diarrhea in HER2+ Breast Cancer

July 12th 2019

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

Novel Strategies Emerging to Tackle Heterogeneity of TNBC

July 8th 2019

Kari B. Wisinski, MD, highlights modern day approaches for treating patients with metastatic triple-negative breast cancer.

Atezolizumab Combo Approaches EU Approval for Frontline TNBC

June 28th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Bypassing Endocrine Resistance in Advanced HR+ Breast Cancer

June 25th 2019

Christopher R. Chitambar, MD, FACP, discusses the research that led to the development of CDK4/6 inhibitors in metastatic HR-positive, HER2-negative breast cancer and the significance of the PI3K inhibitor alpelisib.